Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Dexcom ( (DXCM) ) just unveiled an announcement.
On May 14, 2026, Dexcom held its 2026 Investor Day in Mesa, Arizona, where it outlined market opportunities, business strategy, innovation priorities, and a long-term financial outlook. The company set new long-range financial targets through 2030, including annual organic revenue growth of at least 10%, non-GAAP gross profit margins of 67–69%, non-GAAP operating profit margins of 29–30%, and adjusted EBITDA margins of 36–37%, signaling an ambition to expand profitability as it scales.
Dexcom also announced on May 14, 2026, that its board authorized a new share repurchase program of up to $1.0 billion, with a repurchase period ending no later than June 30, 2027, replacing a prior program that had $250 million remaining. The move gives management flexibility to return capital to shareholders and may support the stock by reducing share count, though the company is not obligated to complete any specific amount of repurchases and may adjust the program based on market conditions.
The most recent analyst rating on (DXCM) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
The score is driven by strong financial performance (higher profitability, accelerating free cash flow, and reduced leverage) and a positive earnings call with raised margin targets. These strengths are tempered by weak technical trends (below key moving averages with negative MACD) and a premium valuation (P/E ~31) that increases sensitivity to any growth or reimbursement timing disappointments.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
DexCom, Inc. is a medical technology company specializing in continuous glucose monitoring systems for people with diabetes. The company focuses on developing and commercializing sensor-based glucose monitoring products, targeting both domestic and international healthcare markets with an emphasis on innovation and long-term growth in diabetes management.
Average Trading Volume: 4,460,599
Technical Sentiment Signal: Sell
Current Market Cap: $22.31B
For an in-depth examination of DXCM stock, go to TipRanks’ Overview page.